NICE is urged to rethink on asthma

Asthma UK has criticised NICE's decision not to recommend the use of omalizumab (Xolair) for children under 12.

NICE has been criticised by Asthma UK
NICE has been criticised by Asthma UK

NICE said the drug provides 'little additional benefit over existing drugs' and due to its high cost does not represent value for money.

Asthma UK said the drug had 'transformed people's lives' and had been approved for use by the Scottish Medicines Consortium.

But NICE said that only a small number of 1.1 million children with asthma in the UK would be eligible for treatment.

Omalizumab is used to treat severe, allergic asthma, where patients have an oversensitive immune system.

Gloucestershire GP Dr Mike Thomas, chief medical adviser to Asthma UK, said he was 'very disappointed' by the decision.

'Those with conditions like severe asthma are held back by crippling daily symptoms, endless trips to hospital and huge amounts of time off school.

'(Omalizumab) could provide a lifeline for some of these children, giving them an opportunity to experience a normal childhood and take part in activities that have been difficult or even impossible.

'We therefore urge NICE to reconsider this decision as a matter of priority.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...